Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 30 for:    vitamin D | COVID-19
Previous Study | Return to List | Next Study

Vitamin D and COVID-19 Management

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04385940
Recruitment Status : Not yet recruiting
First Posted : May 13, 2020
Last Update Posted : June 5, 2020
Sponsor:
Information provided by (Responsible Party):
Aldo Montano-Loza, University of Alberta

Brief Summary:

A novel coronavirus disease 2019 (COVID-19) outbreak is a global dramatic pandemic that is immeasurably impacting the communities. Due to lack of data, symptomatic management is used for COVID-19 infection including oxygen therapy and mechanical ventilation for those with severe infection. Considering immunomodulatory, anti-inflammatory anti-fibrotic and anti-oxidant actions of vitamin D, it's safety and ease of administration, as well as direct effects of vitamin D on immune cell proliferation and activity, pulmonary ACE2 expression and reducing surface tension, evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be of substantial clinical and economic significance. High prevalence of vitamin D deficiency in elderly, smokers, patients with chronic diseases and excess uptake by adipose tissue in obesity make investigations of its role as a secondary therapeutic agent in COVID-19 conceivable. It should be necessary to monitor serum 25(OH)D levels in all inpatient and outpatient populations with COVID-19 to identify the importance of maintaining or promptly increasing circulating levels of 25(OH)D into the optimal range of 100-150 nmol/L.

The aim of this study is to conduct a double blind, randomized, controlled three weeks clinical trial on the efficacy of vitamin D (daily low dose versus weekly high dose) in COVID-19 patients in order to determine the relationship between baseline vitamin D deficiency and clinical characteristics and to asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery.

Subjects who are randomized to high-dose will be asked to take 50,000 IU for two times during the first week and one dose over second and third weeks to quickly raise their serum levels. Subjects in the low-dose arm will take vitamin D 1000 IU daily for three weeks.


Condition or disease Intervention/treatment Phase
COVID-19 Dietary Supplement: Ddrops® products, 50,000 IU, Oral Dietary Supplement: Vitamin D3 Phase 3

Detailed Description:

In-patients

  1. Determine the frequency of low serum Vit D levels (<50 nmol/L) in COVID-19 patients.
  2. Determine the relationship between baseline vitamin D status and disease severity, laboratory biochemical tests of white blood cell count (WBC), C-reactive protein (CRP), lymphocyte count, leukocytes counts and neutrophil-lymphocyte-ratio (NLR), lactate dehydrogenase, IL-6, IL-1beta, TNF-alpha platelet count, albumin, and serum ferritin, required hospitalization and intensive care unit (ICU) admission.
  3. Asses patients' initial response to vitamin D supplementation in week one and determine its association with disease progression and recovery.
  4. Compare disease severity and progression, laboratory biochemical tests of white blood cell count (WBC), C-reactive protein (CRP), lymphocyte count, lactate dehydrogenase, IL-6, IL-1beta, TNF-alpha, platelet count, albumin, and serum ferritin, hospital admission and length of stay, duration of mechanical ventilation, hospital mortality and respiratory failure differ between the early responder and non-responder groups.

Out-patients

  1. Determine the frequency of low serum Vit D levels (<50 nmol/L) in COVID-19 patients.
  2. Determine the relationship between baseline vitamin D deficiency and clinical characteristics.
  3. Asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improving Vitamin D Status in the Management of COVID-19
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D

Arm Intervention/treatment
Experimental: High dose vitamin D
Ddrops® products,Vitamin D3, 50,000 IU, Oral
Dietary Supplement: Ddrops® products, 50,000 IU, Oral
Vitamin D3

Active Comparator: Low dose vitamin D
Vitamin D3 1000IU
Dietary Supplement: Vitamin D3
Vitamin D3 1000IU




Primary Outcome Measures :
  1. Symptoms recovery [ Time Frame: Time from onset of intervention to day 21 ]
    Number of Participants whose symptoms recovered over three weeks


Secondary Outcome Measures :
  1. Hospitalization [ Time Frame: Between diagnosis and day 21 ]
    Number of patients who required hospitalization

  2. Blood white blood cell count (WBC) [ Time Frame: At day 0 before starting intervention and day 21 of intervention ]
    x 109/L

  3. Duration of mechanical ventilation [ Time Frame: Between diagnosis and day 21 ]
    If patients required mechanical ventilation at any time after diagnosis

  4. Duration of hospitalization [ Time Frame: Between diagnosis and day 21 ]
    Length of stay in hospital (days)

  5. Intensive care unit (ICU) admission [ Time Frame: Between diagnosis and day 21 ]
    Number of patients who required ICU

  6. Duration of ICU stay [ Time Frame: Between diagnosis and day 21 ]
    Length of stay in ICU

  7. Blood C-reactive protein (CRP) [ Time Frame: Baseline and day 21 ]
    mg/L

  8. Blood Lymphocyte count [ Time Frame: Baseline and day 21 ]
    number of lymphocytes in 1 microliter (µL) of blood

  9. Blood Ferritin [ Time Frame: Baseline and day 21 ]
    ng/mL

  10. Blood platelet count [ Time Frame: Baseline and day 21 ]
    platelets per microliter of blood

  11. Blood interleukin-6 (IL-6) [ Time Frame: Baseline and day 21 ]
    pg/mL

  12. Blood Tumor Necrosis Factor alpha (TNF) [ Time Frame: Baseline and day 21 ]
    pg/ml



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   17 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with COVID-19:

  • ≥ 17 years old
  • Both sexes

Exclusion Criteria:

  • Patients with dementia, learning disability, mental health needs and alcohol or drug dependency, pregnant women will be excluded.
  • Patients with sarcoidosis, hypercalcemia, known vitamin D intolerance
Layout table for additonal information
Responsible Party: Aldo Montano-Loza, Associate Professor of Medicine, Program Director of Hepatology, University of Alberta
ClinicalTrials.gov Identifier: NCT04385940    
Other Study ID Numbers: 00100606
First Posted: May 13, 2020    Key Record Dates
Last Update Posted: June 5, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin D
Cholecalciferol
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents